Status: Not yet recruiting
First-line Therapy With EGFR-TKI Combined With Trastuzumab Rezetecan for Advanced NSCLC Harboring EGFR Mutations Concomitant With HER2 Alterations
To explore the efficacy and safety of first-line EGFR-TKI combined with Trastuzumab Rezetecan in advanced NSCLC patients harboring EGFR mutations with concomitant HER2 genomic alterations or HER2 protein expression (1+/2+/3+)
Participants needed: 35
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Yongsheng WangUpdated: Jul 13, 2026
Eligibility criteria
Aged 18-75 years, male or female without restriction; [+8]
Histologically confirmed tumor containing small cell lung cancer components. [+3]